Clinical value of serum AFP and PIVKA-II for diagnosis, treatment and prognosis of hepatocellular carcinoma.
作者信息
Jin Yujiao, Xu Aifang
机构信息
Department of Clinical Laboratory, Xixi Hospital of Hangzhou, Hangzhou, China.
出版信息
J Clin Lab Anal. 2024 Feb;38(4):e25016. doi: 10.1002/jcla.25016. Epub 2024 Feb 23.
Abstract
摘要
相似文献
1
Clinical value of serum AFP and PIVKA-II for diagnosis, treatment and prognosis of hepatocellular carcinoma.血清甲胎蛋白和异常凝血酶原在肝细胞癌诊断、治疗及预后中的临床价值
J Clin Lab Anal. 2024 Feb;38(4):e25016. doi: 10.1002/jcla.25016. Epub 2024 Feb 23.
2
PIVKA-II serves as a potential biomarker that complements AFP for the diagnosis of hepatocellular carcinoma.PIVKA-II 可作为 AFP 的补充生物标志物，用于肝癌的诊断。
BMC Cancer. 2021 Apr 13;21(1):401. doi: 10.1186/s12885-021-08138-3.
3
Clinical characteristics and prognosis of hepatocellular carcinoma with different sets of serum AFP and PIVKA-II levels.不同 AFP 和 PIVKA-II 血清水平组合的肝细胞癌的临床特征和预后。
Eur J Gastroenterol Hepatol. 2012 Jul;24(7):849-56. doi: 10.1097/MEG.0b013e3283535c34.
4
Clinical evaluation of plasma des-gamma-carboxy prothrombin as a marker protein of hepatocellular carcinoma in patients with tumors of various sizes.血浆去γ-羧基凝血酶原作为不同大小肿瘤患者肝细胞癌标志物蛋白的临床评价。
Dig Dis Sci. 1993 Dec;38(12):2170-6. doi: 10.1007/BF01299891.
5
Diagnostic value of serum PIVKA-II levels for BCLC early hepatocellular carcinoma and correlation with HBV DNA.血清 PIVKA-II 水平对 BCLC 早期肝细胞癌的诊断价值及其与 HBV DNA 的相关性。
Cancer Biomark. 2018;23(2):235-242. doi: 10.3233/CBM-181402.
6
Diagnostic value of AFP-L3 and PIVKA-II in hepatocellular carcinoma according to total-AFP.甲胎蛋白异质体 3 和异常凝血酶原在总甲胎蛋白指导下对肝细胞癌的诊断价值。
World J Gastroenterol. 2013 Jan 21;19(3):339-46. doi: 10.3748/wjg.v19.i3.339.
7
Clinical value of serum AFP and PIVKA-II for diagnosis, treatment and prognosis of hepatocellular carcinoma.血清 AFP 和 PIVKA-II 对肝细胞癌的诊断、治疗和预后的临床价值。
J Clin Lab Anal. 2023 Jan;37(1):e24823. doi: 10.1002/jcla.24823. Epub 2022 Dec 29.
8
[Tumor markers for hepatocellular carcinoma].[肝细胞癌的肿瘤标志物]
Nihon Rinsho. 2012 May;70(5):821-7.
9
Diagnostic value of gamma-glutamyltransferase/aspartate aminotransferase ratio, protein induced by vitamin K absence or antagonist II, and alpha-fetoprotein in hepatitis B virus-related hepatocellular carcinoma.γ-谷氨酰转移酶/天冬氨酸氨基转移酶比值、维生素 K 拮抗剂 II 诱导蛋白与甲胎蛋白在乙型肝炎病毒相关性肝细胞癌中的诊断价值。
World J Gastroenterol. 2019 Sep 28;25(36):5515-5529. doi: 10.3748/wjg.v25.i36.5515.
10
Modeling the time-related fluctuations of AFP and PIVKA-II serum levels in patients with cirrhosis undergoing surveillance for hepatocellular carcinoma.对接受肝细胞癌监测的肝硬化患者血清甲胎蛋白（AFP）和异常凝血酶原（PIVKA-II）水平的时间相关波动进行建模。
Cancer Biomark. 2020;29(2):189-196. doi: 10.3233/CBM-190118.
引用本文的文献
1
Comparison of initial treatments for resectable hepatocellular carcinoma within Milan criteria: an observational study based on a nationwide survey.米兰标准内可切除肝细胞癌初始治疗方法的比较：一项基于全国性调查的观察性研究
Ann Surg Treat Res. 2025 May;108(5):279-294. doi: 10.4174/astr.2025.108.5.279. Epub 2025 Apr 28.
本文引用的文献
1
Clinical value of serum AFP and PIVKA-II for diagnosis, treatment and prognosis of hepatocellular carcinoma.血清 AFP 和 PIVKA-II 对肝细胞癌的诊断、治疗和预后的临床价值。
J Clin Lab Anal. 2023 Jan;37(1):e24823. doi: 10.1002/jcla.24823. Epub 2022 Dec 29.
Zotero 插件